ARTICLE | Clinical News
Lorvotuzumab mertansine: Phase I/II started
December 13, 2010 8:00 AM UTC
ImmunoGen began a dose-escalation, international Phase I/II trial to compare weekly IMGN901 given for the first 2 weeks in a 3-week cycle plus standard of care (SOC; carboplatin and etoposide) vs. SOC...